FDA Drops Boxed Warning on LABA/ICS Asthma/COPD Meds FDA Drops Boxed Warning on LABA/ICS Asthma/COPD Meds
FDA-required postmarket safety studies find no increased risk for serious asthma-related outcomes with products containing a long-acting beta-agonist and inhaled corticosteroid.News Alerts
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Pulmonary Medicine News Alert Source Type: news
More News: Asthma | Chronic Obstructive Pulmonary | Corticosteroid Therapy | Health | Study | Warnings